307 related articles for article (PubMed ID: 21632862)
1. Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design.
Mineharu Y; King GD; Muhammad AK; Bannykh S; Kroeger KM; Liu C; Lowenstein PR; Castro MG
Clin Cancer Res; 2011 Jul; 17(14):4705-18. PubMed ID: 21632862
[TBL] [Abstract][Full Text] [Related]
2. Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics.
Candolfi M; King GD; Yagiz K; Curtin JF; Mineharu Y; Muhammad AK; Foulad D; Kroeger KM; Barnett N; Josien R; Lowenstein PR; Castro MG
Neoplasia; 2012 Aug; 14(8):757-70. PubMed ID: 22952428
[TBL] [Abstract][Full Text] [Related]
3. Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model.
Mineharu Y; Muhammad AK; Yagiz K; Candolfi M; Kroeger KM; Xiong W; Puntel M; Liu C; Levy E; Lugo C; Kocharian A; Allison JP; Curran MA; Lowenstein PR; Castro MG
Neurotherapeutics; 2012 Oct; 9(4):827-43. PubMed ID: 22996231
[TBL] [Abstract][Full Text] [Related]
4. HMGB1 mediates endogenous TLR2 activation and brain tumor regression.
Curtin JF; Liu N; Candolfi M; Xiong W; Assi H; Yagiz K; Edwards MR; Michelsen KS; Kroeger KM; Liu C; Muhammad AK; Clark MC; Arditi M; Comin-Anduix B; Ribas A; Lowenstein PR; Castro MG
PLoS Med; 2009 Jan; 6(1):e10. PubMed ID: 19143470
[TBL] [Abstract][Full Text] [Related]
5. Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity.
Candolfi M; Yagiz K; Foulad D; Alzadeh GE; Tesarfreund M; Muhammad AK; Puntel M; Kroeger KM; Liu C; Lee S; Curtin JF; King GD; Lerner J; Sato K; Mineharu Y; Xiong W; Lowenstein PR; Castro MG
Clin Cancer Res; 2009 Jul; 15(13):4401-14. PubMed ID: 19570774
[TBL] [Abstract][Full Text] [Related]
6. Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits.
King GD; Kroeger KM; Bresee CJ; Candolfi M; Liu C; Manalo CM; Muhammad AK; Pechnick RN; Lowenstein PR; Castro MG
Mol Ther; 2008 Apr; 16(4):682-90. PubMed ID: 18283279
[TBL] [Abstract][Full Text] [Related]
7. An autologous in situ tumor vaccination approach for hepatocellular carcinoma. 1. Flt3 ligand gene transfer increases antitumor effects of a radio-inducible suicide gene therapy in an ectopic tumor model.
Kawashita Y; Deb NJ; Garg M; Kabarriti R; Alfieri A; Takahashi M; Roy-Chowdhury J; Guha C
Radiat Res; 2014 Aug; 182(2):191-200. PubMed ID: 24972258
[TBL] [Abstract][Full Text] [Related]
8. A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeutics.
Puntel M; Muhammad AK; Candolfi M; Salem A; Yagiz K; Farrokhi C; Kroeger KM; Xiong W; Curtin JF; Liu C; Bondale NS; Lerner J; Pechnick RN; Palmer D; Ng P; Lowenstein PR; Castro MG
J Virol; 2010 Jun; 84(12):6007-17. PubMed ID: 20375153
[TBL] [Abstract][Full Text] [Related]
9. Blockade of mTOR signaling via rapamycin combined with immunotherapy augments antiglioma cytotoxic and memory T-cell functions.
Mineharu Y; Kamran N; Lowenstein PR; Castro MG
Mol Cancer Ther; 2014 Dec; 13(12):3024-36. PubMed ID: 25256739
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models.
Candolfi M; Yagiz K; Wibowo M; Ahlzadeh GE; Puntel M; Ghiasi H; Kamran N; Paran C; Lowenstein PR; Castro MG
Clin Cancer Res; 2014 Mar; 20(6):1555-1565. PubMed ID: 24501391
[TBL] [Abstract][Full Text] [Related]
11. Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials.
Curtin JF; Candolfi M; Fakhouri TM; Liu C; Alden A; Edwards M; Lowenstein PR; Castro MG
PLoS One; 2008 Apr; 3(4):e1983. PubMed ID: 18431473
[TBL] [Abstract][Full Text] [Related]
12. Human Flt3L generates dendritic cells from canine peripheral blood precursors: implications for a dog glioma clinical trial.
Xiong W; Candolfi M; Liu C; Muhammad AK; Yagiz K; Puntel M; Moore PF; Avalos J; Young JD; Khan D; Donelson R; Pluhar GE; Ohlfest JR; Wawrowsky K; Lowenstein PR; Castro MG
PLoS One; 2010 Jun; 5(6):e11074. PubMed ID: 20552015
[TBL] [Abstract][Full Text] [Related]
13. An autologous in situ tumor vaccination approach for hepatocellular carcinoma. 2. Tumor-specific immunity and cure after radio-inducible suicide gene therapy and systemic CD40-ligand and Flt3-ligand gene therapy in an orthotopic tumor model.
Kawashita Y; Deb NJ; Garg MK; Kabarriti R; Fan Z; Alfieri AA; Roy-Chowdhury J; Guha C
Radiat Res; 2014 Aug; 182(2):201-10. PubMed ID: 24992166
[TBL] [Abstract][Full Text] [Related]
14. Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model.
King GD; Muhammad AK; Curtin JF; Barcia C; Puntel M; Liu C; Honig SB; Candolfi M; Mondkar S; Lowenstein PR; Castro MG
Neuro Oncol; 2008 Feb; 10(1):19-31. PubMed ID: 18079358
[TBL] [Abstract][Full Text] [Related]
15. B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma.
Candolfi M; Curtin JF; Yagiz K; Assi H; Wibowo MK; Alzadeh GE; Foulad D; Muhammad AK; Salehi S; Keech N; Puntel M; Liu C; Sanderson NR; Kroeger KM; Dunn R; Martins G; Lowenstein PR; Castro MG
Neoplasia; 2011 Oct; 13(10):947-60. PubMed ID: 22028620
[TBL] [Abstract][Full Text] [Related]
16. Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression.
Ghulam Muhammad AK; Candolfi M; King GD; Yagiz K; Foulad D; Mineharu Y; Kroeger KM; Treuer KA; Nichols WS; Sanderson NS; Yang J; Khayznikov M; Van Rooijen N; Lowenstein PR; Castro MG
Clin Cancer Res; 2009 Oct; 15(19):6113-27. PubMed ID: 19789315
[TBL] [Abstract][Full Text] [Related]
17. Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen.
King GD; Muhammad AK; Larocque D; Kelson KR; Xiong W; Liu C; Sanderson NS; Kroeger KM; Castro MG; Lowenstein PR
Mol Ther; 2011 Oct; 19(10):1793-801. PubMed ID: 21505426
[TBL] [Abstract][Full Text] [Related]
18. Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.
Batich KA; Reap EA; Archer GE; Sanchez-Perez L; Nair SK; Schmittling RJ; Norberg P; Xie W; Herndon JE; Healy P; McLendon RE; Friedman AH; Friedman HS; Bigner D; Vlahovic G; Mitchell DA; Sampson JH
Clin Cancer Res; 2017 Apr; 23(8):1898-1909. PubMed ID: 28411277
[No Abstract] [Full Text] [Related]
19. Preclinical Efficacy and Safety Profile of Allometrically Scaled Doses of Doxycycline Used to Turn "On" Therapeutic Transgene Expression from High-Capacity Adenoviral Vectors in a Glioma Model.
VanderVeen N; Raja N; Yi E; Appelman H; Ng P; Palmer D; Zamler D; Dzaman M; Lowenstein PR; Castro MG
Hum Gene Ther Methods; 2016 Jun; 27(3):98-111. PubMed ID: 27056322
[TBL] [Abstract][Full Text] [Related]
20. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
